Iqvia (NYSE:IQV) updated its FY 2020
Pre-Market earnings guidance on Wednesday. The company provided earnings per share guidance of 7.15-7.35 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $7.25. The company issued revenue guidance of $11.775-12 billion, compared to the consensus revenue estimate of $11.84 billion.Iqvia also updated its FY20 guidance to $7.15-7.35 EPS.
Several research firms recently weighed in on IQV. Zacks Investment Research upgraded shares of Iqvia from a sell rating to a hold rating and set a $170.00 price target on the stock in a report on Tuesday, February 4th. Credit Suisse Group reissued a buy rating and set a $170.00 price objective on shares of Iqvia in a research report on Friday, December 20th. Stifel Nicolaus upped their price objective on shares of Iqvia from to and gave the stock a buy rating in a report on Wednesday. Wells Fargo & Co assumed coverage on shares of Iqvia in a research note on Tuesday, January 7th. They set an overweight rating and a $180.00 target price on the stock. Finally, JPMorgan Chase & Co. lifted their target price on shares of Iqvia from $180.00 to $195.00 and gave the company an overweight rating in a research note on Thursday. Three investment analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. The company presently has a consensus rating of Buy and an average target price of $174.30.
Shares of Iqvia stock opened at $164.32 on Friday. The company has a current ratio of 1.05, a quick ratio of 1.12 and a debt-to-equity ratio of 1.91. The firm has a market capitalization of $32.17 billion, a P/E ratio of 28.53, a P/E/G ratio of 1.76 and a beta of 0.91. The business has a fifty day simple moving average of $158.20 and a two-hundred day simple moving average of $151.72. Iqvia has a 12 month low of $130.77 and a 12 month high of $169.14.
Iqvia (NYSE:IQV) last released its earnings results on Wednesday, February 12th. The medical research company reported $1.74 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.72 by $0.02. Iqvia had a net margin of 1.72% and a return on equity of 17.65%. The firm had revenue of $2.90 billion for the quarter, compared to the consensus estimate of $2.85 billion. During the same period in the prior year, the firm earned $1.50 EPS. The company’s revenue was up 7.7% compared to the same quarter last year. Analysts predict that Iqvia will post 6.81 earnings per share for the current year.
In other Iqvia news, CFO Michael R. Mcdonnell sold 12,000 shares of the business’s stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $155.07, for a total value of $1,860,840.00. Following the sale, the chief financial officer now directly owns 14,366 shares of the company’s stock, valued at $2,227,735.62. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Michael J. Evanisko sold 6,250 shares of the stock in a transaction on Friday, January 10th. The stock was sold at an average price of $160.08, for a total value of $1,000,500.00. The disclosure for this sale can be found here. In the last 90 days, insiders sold 37,000 shares of company stock worth $5,830,215. Corporate insiders own 6.00% of the company’s stock.
Iqvia Company Profile
IQVIA Holdings Inc provides advanced analytics, technology solutions, and contract research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
Read More: Quiet Period
Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.